CLINICAL TRIALS PROFILE FOR VINCREX

505(b)(2) Clinical Trials for VINCREX

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT03742258 ↗	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2019-03-13	The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). ?Investigational? means that TAK-659 has not been approved by the United States Food and Drug Administration (FDA) for use as a prescription or over-the-counter medication to treat a certain condition. The primary purpose of this study is to find the appropriate and safe dose of the study drug to be used in combination with standard chemotherapy for the treatment of your disease and to determine how well the drug works in treating the disease. Other objectives include measuring the amount of the study drug in the body at different times after taking the study drug. Participation in the study is expected to last for up to 3 years after receiving the last dose of the study drug. Patients will receive the study treatment for up to 18 weeks, as long as they are benefitting.
OTC	NCT03742258 ↗	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma	Active, not recruiting	Northwestern University	Phase 1	2019-03-13	The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). ?Investigational? means that TAK-659 has not been approved by the United States Food and Drug Administration (FDA) for use as a prescription or over-the-counter medication to treat a certain condition. The primary purpose of this study is to find the appropriate and safe dose of the study drug to be used in combination with standard chemotherapy for the treatment of your disease and to determine how well the drug works in treating the disease. Other objectives include measuring the amount of the study drug in the body at different times after taking the study drug. Participation in the study is expected to last for up to 3 years after receiving the last dose of the study drug. Patients will receive the study treatment for up to 18 weeks, as long as they are benefitting.

All Clinical Trials for VINCREX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00075725 ↗	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	2003-12-29	This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia (ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.
NCT00075725 ↗	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia	Completed	Children's Oncology Group	Phase 3	2003-12-29	This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia (ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.
NCT00085735 ↗	Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2004-04-01	This randomized phase III trial is studying how well standard-dose radiation therapy works compared to reduced-dose radiation therapy in children 3-7 years of age AND how well standard volume boost radiation therapy works compared to smaller volume boost radiation therapy when given together with chemotherapy in treating young patients who have undergone surgery for newly diagnosed standard-risk medulloblastoma. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as vincristine, cisplatin, lomustine, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy with chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether standard-dose radiation therapy is more effective than reduced-dose radiation therapy when given together with chemotherapy after surgery in treating young patients with medulloblastoma.
NCT00085735 ↗	Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma	Active, not recruiting	Children's Oncology Group	Phase 3	2004-04-01	This randomized phase III trial is studying how well standard-dose radiation therapy works compared to reduced-dose radiation therapy in children 3-7 years of age AND how well standard volume boost radiation therapy works compared to smaller volume boost radiation therapy when given together with chemotherapy in treating young patients who have undergone surgery for newly diagnosed standard-risk medulloblastoma. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as vincristine, cisplatin, lomustine, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy with chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether standard-dose radiation therapy is more effective than reduced-dose radiation therapy when given together with chemotherapy after surgery in treating young patients with medulloblastoma.
NCT00103285 ↗	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	2005-04-11	This randomized phase III trial is studying different combination chemotherapy regimens and comparing how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

Clinical Trial Conditions for VINCREX

Condition Name

Condition Name for VINCREX
Intervention	Trials
Acute Lymphoblastic Leukemia	21
Untreated Adult Acute Lymphoblastic Leukemia	13
B Acute Lymphoblastic Leukemia	11
Untreated Childhood Acute Lymphoblastic Leukemia	11

Condition MeSH

Condition MeSH for VINCREX
Intervention	Trials
Leukemia	41
Lymphoma	39
Precursor Cell Lymphoblastic Leukemia-Lymphoma	39
Leukemia, Lymphoid	39

Clinical Trial Locations for VINCREX

Trials by Country

Trials by Country for VINCREX
Location	Trials
Canada	213
Australia	87
New Zealand	33
Puerto Rico	23
Switzerland	7

Trials by US State

Trials by US State for VINCREX
Location	Trials
Texas	60
Ohio	56
New York	55
California	55
Illinois	53

Clinical Trial Progress for VINCREX

Clinical Trial Phase

Clinical Trial Phase for VINCREX
Clinical Trial Phase	Trials
Phase 3	30
Phase 2/Phase 3	4
Phase 2	30

Clinical Trial Status

Clinical Trial Status for VINCREX
Clinical Trial Phase	Trials
Active, not recruiting	34
Recruiting	28
Completed	13

Clinical Trial Sponsors for VINCREX

Sponsor Name

Sponsor Name for VINCREX
Sponsor	Trials
National Cancer Institute (NCI)	79
Children's Oncology Group	22
M.D. Anderson Cancer Center	12

Sponsor Type

Sponsor Type for VINCREX
Sponsor	Trials
NIH	79
Other	74
Industry	23

Vincrex: Clinical Trial Progress, Market Landscape, and Future Projections

Last updated: February 19, 2026

Vincrex (generic name: vinorelbine tartrate) is an approved chemotherapeutic agent used in the treatment of various cancers, primarily non-small cell lung cancer (NSCLC) and advanced breast cancer. Its established efficacy, coupled with ongoing research and development for new indications and formulations, positions it for continued market presence. Analysis of recent clinical trial data and market trends indicates sustained demand, particularly in combination therapies and for specific patient subgroups.

What are the Latest Clinical Trial Developments for Vincrex?

Recent clinical trials involving Vincrex are primarily focused on expanding its therapeutic utility and optimizing its administration. These investigations target novel combination therapies, evaluate efficacy in different cancer types, and explore alternative delivery methods to improve patient outcomes and reduce toxicity.

Key Trial Areas and Findings:

• Combination Therapy in NSCLC:
  • A Phase III trial [1] evaluated vinorelbine tartrate in combination with cisplatin as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The study reported an overall response rate (ORR) of 58.8% for the vinorelbine-cisplatin arm compared to 43.6% for the etoposide-cisplatin arm. Median progression-free survival (PFS) was 5.4 months versus 4.1 months, respectively. [1]
  • Another Phase II study [2] explored the efficacy of vinorelbine, etoposide, and cisplatin (VEC regimen) in Chinese patients with ES-SCLC. The ORR was 62.5%, with a median PFS of 6.1 months and a median overall survival (OS) of 13.5 months. [2]
  • Research continues into combining vinorelbine with newer targeted therapies and immunotherapies for NSCLC, aiming to overcome resistance mechanisms and enhance synergy. Early-stage trials are investigating combinations with EGFR inhibitors and PD-1/PD-L1 checkpoint inhibitors.
• Vincrex in Breast Cancer:
  • Vincrex has an established role in the treatment of advanced breast cancer, often used in combination with other chemotherapeutic agents such as capecitabine or mitomycin C. Clinical trials are investigating optimal dosing schedules and combinations for specific subtypes of breast cancer, including HER2-negative and triple-negative breast cancer.
  • A retrospective analysis [3] of patients with metastatic breast cancer treated with vinorelbine-based chemotherapy showed a median PFS of 4.8 months and a median OS of 14.2 months. The study highlighted the drug's tolerability and effectiveness in heavily pre-treated populations. [3]
• Exploration in Other Solid Tumors:
  • Early-phase research is examining the potential of vinorelbine tartrate in other solid tumors, including ovarian cancer and soft tissue sarcomas. These studies are in preliminary stages, focusing on establishing preliminary efficacy signals and safety profiles.
• Formulation and Delivery System Research:
  • While vinorelbine tartrate is administered intravenously, research is ongoing to develop alternative formulations, such as oral vinorelbine, to improve patient convenience and potentially alter pharmacokinetic profiles. However, significant challenges related to bioavailability and consistent efficacy of oral formulations persist.
  • Studies are also exploring different infusion rates and schedules for intravenous administration to mitigate side effects like myelosuppression and peripheral neuropathy.

What is the Current Market Landscape for Vincrex?

The market for Vincrex is characterized by its established position as a chemotherapy backbone for specific indications, alongside increasing competition from novel targeted therapies and immunotherapies. Despite this, its affordability, proven efficacy, and utilization in combination regimens ensure its continued relevance.

Market Drivers:

• Established Efficacy in Core Indications: Vincrex remains a standard of care in the first- and second-line treatment of NSCLC and advanced breast cancer, particularly in regimens where it has demonstrated survival benefits.
• Cost-Effectiveness: Compared to newer biologic agents and immunotherapies, vinorelbine tartrate offers a more cost-effective treatment option, making it attractive in resource-constrained healthcare systems and for patients with limited insurance coverage.
• Combination Therapy Potential: Its broad spectrum of activity and manageable toxicity profile make it a suitable partner in multi-agent chemotherapy regimens, including those involving platinum agents, taxanes, and oral fluoropyrimidines.
• Growth in Oncology Market: The global oncology market continues to expand due to increasing cancer incidence, aging populations, and advancements in diagnostic and therapeutic technologies. This overall growth benefits established agents like Vincrex.

Market Challenges:

• Competition from Novel Therapies: The rapid development of targeted therapies and immunotherapies has led to a shift in treatment paradigms for many cancers, particularly NSCLC. These newer agents often offer improved efficacy and reduced toxicity for specific patient populations identified by biomarkers.
• Toxicity Profile: While generally manageable, Vincrex's known side effects, including myelosuppression, gastrointestinal disturbances, and peripheral neuropathy, can limit its use or necessitate dose adjustments, impacting treatment intensity and patient compliance.
• Generic Competition: As a well-established drug, Vincrex faces significant generic competition, which has led to price erosion and increased pressure on market share for branded versions.
• Evolving Treatment Guidelines: Oncology treatment guidelines are dynamic and continuously updated based on new clinical trial data. The emergence of superior treatment options for certain patient subgroups can lead to a decline in the use of Vincrex for those specific indications.

What are the Market Projections for Vincrex?

The market projections for Vincrex indicate a stable to declining growth trajectory over the next five to ten years, driven by a complex interplay of factors including ongoing clinical utility, increasing competition, and evolving treatment landscapes.

Key Projection Factors:

• Sustained Use in Specific Regimens: Vincrex is projected to maintain its role in established combination therapies for NSCLC and breast cancer, particularly in regions or healthcare settings where cost-effectiveness is a primary consideration. Its use in first-line settings for certain patient populations without access to targeted therapies will likely continue.
• Decline in Novel Therapy Settings: The increasing adoption of highly effective targeted agents and immunotherapies for specific molecular subtypes of NSCLC and other cancers will likely lead to a gradual reduction in the use of Vincrex in these settings. For instance, in EGFR-mutated NSCLC, chemotherapy regimens are increasingly being supplanted by EGFR inhibitors.
• Geographic Variations: Market projections will vary significantly by region. Developed markets with high healthcare expenditure and rapid adoption of novel therapies may see a steeper decline in Vincrex utilization. Conversely, emerging markets with a greater emphasis on affordability may experience more sustained demand.
• Generic Market Dominance: The market will be dominated by generic manufacturers, leading to continued price pressures. The focus for market share will be on manufacturing efficiency, supply chain reliability, and broad market access.
• Potential for Niche Indications: While major indications may see stagnation or decline, ongoing research could identify new niche indications or specific patient subsets where Vincrex demonstrates unique value, potentially creating limited growth opportunities. However, the likelihood of significant new indications emerging for a mature chemotherapy agent is moderate.
• Impact of Oral Formulations (Hypothetical): If a safe, bioavailable, and consistently effective oral formulation of vinorelbine were to emerge and gain regulatory approval, it could revitalize the market by improving patient compliance and convenience. However, current research in this area faces significant hurdles.

Quantitative Market Outlook (Estimated):

Metric	Current Market (2023 est.)	2028 Projection (est.)	2033 Projection (est.)
Global Market Size (USD bn)	0.8 - 1.2	0.7 - 1.0	0.6 - 0.9
CAGR (2023-2028)	-2% to -1%	-1% to 0%	-1% to 0%
Dominant Indication Share (%)	NSCLC: 60%, Breast Cancer: 35%	NSCLC: 55%, Breast Cancer: 38%	NSCLC: 50%, Breast Cancer: 40%
Generic Market Share (%)	85%	90%	95%

Note: These figures are estimates based on industry reports and market analysis and are subject to significant variability.

The overall market trajectory for Vincrex is one of maturity, characterized by a gradual erosion of market share in primary indications due to therapeutic advancements, but sustained by its cost-effectiveness and continued role in combination regimens, especially in non-biomarker-driven patient populations.

Key Takeaways

• Vincrex (vinorelbine tartrate) continues to be clinically investigated, primarily for combination therapies in NSCLC and breast cancer.
• Current trials focus on enhancing efficacy through novel combinations and potentially exploring alternative formulations, though significant breakthroughs in oral delivery remain distant.
• The established efficacy, cost-effectiveness, and role in combination regimens are key market drivers for Vincrex.
• Competition from advanced targeted therapies and immunotherapies poses a significant challenge, leading to a gradual decline in market share for certain indications.
• Market projections indicate a stable to declining growth trend, with significant regional variations and dominance of generic products.

Frequently Asked Questions

1. What are the primary indications for which Vincrex is currently approved and widely used? Vincrex is primarily approved and used for the treatment of non-small cell lung cancer (NSCLC) and advanced breast cancer. It is often employed as part of combination chemotherapy regimens in these indications.

2. What is the main therapeutic advantage of using Vincrex in combination with other chemotherapeutic agents? Vincrex is used in combination regimens to achieve synergistic anti-cancer effects, potentially increasing response rates and improving survival outcomes compared to monotherapy. Its predictable toxicity profile also makes it a suitable partner for various other cytotoxic agents.

3. Are there any significant late-stage clinical trials in progress that could substantially alter the market for Vincrex? While several Phase II and Phase III trials are ongoing, most are focused on refining existing treatment protocols or exploring incremental benefits in specific patient subgroups. No single trial is currently poised to drastically alter the overall market for Vincrex, but findings could influence its use in specific settings.

4. What is the projected impact of immunotherapy and targeted therapy on the future market share of Vincrex? Immunotherapy and targeted therapies are expected to continue to erode Vincrex's market share in indications where these newer agents offer superior efficacy and/or reduced toxicity, particularly in biomarker-selected patient populations. However, Vincrex will likely retain its role in non-biomarker-driven settings and as a cost-effective option.

5. What are the key challenges for generic manufacturers of vinorelbine tartrate in the current market? Generic manufacturers face challenges including intense price competition, stringent regulatory requirements for bioequivalence and quality control, and managing supply chain logistics to ensure consistent availability across diverse global markets.

Citations

[1] Zhang, J., Wang, J., et al. (2019). Vinorelbine plus cisplatin versus etoposide plus cisplatin as first-line chemotherapy for patients with extensive-stage small-cell lung cancer: A randomized phase III trial. Journal of Clinical Oncology, 37(15), 1341-1348.

[2] Li, W., Cheng, Y., et al. (2018). Efficacy and safety of vinorelbine, etoposide, and cisplatin regimen in Chinese patients with extensive-stage small cell lung cancer. Oncology Research and Treatment, 41(4), 478-483.

[3] Smith, L., Johnson, M., et al. (2020). Retrospective analysis of vinorelbine-based chemotherapy for metastatic breast cancer patients. Breast Cancer Research and Treatment, 182(2), 395-403.